GlassScriptPhysician profile
Jeffrey D Rednor
NPI 1184648149
$1,610.83
in general payments reported to CMS, 2019-2025
12 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $292 · 2021: $320 · 2022: $196 · 2023: $148 · 2024: $171 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $353.07 | 2019-2022 | |
| Lilly USA, LLC | $303.09 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $265.75 | 2019-2024 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $142.72 | 2020-2022 | |
| Novo Nordisk INC | $135.37 | 2019-2020 | |
| Amgen INC. | $122.09 | 2023 | Evenity |
| Janssen Biotech, INC. | $120.80 | 2025 | Tremfya, Simponi Aria |
| Allergan, INC. | $59.89 | 2019-2020 | |
| Pfizer INC. | $52.94 | 2019 | |
| Merck Sharp & Dohme LLC | $26.82 | 2021 | |
| Glaxosmithkline, LLC. | $14.47 | 2024 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rednor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.